Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shorter blood thinner course after aneurysm coiling may be just as safe

NCT ID NCT05257824

Disease control Sponsor: Seoul National University Bundang Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 528 adults who had a brain aneurysm fixed with a stent and coils. It compared taking two blood thinners for 6 months versus 12 months after the procedure. The goal was to see if the shorter course could prevent blood clots just as well while reducing bleeding risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

528 people

The number who actually took part.

Started

Jun 2022

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * subjects over 19 years old * subjects with modified Rankin Scale (mRS) ≤ 2 * subjects with unruptured intracranial aneurysms * subjects with appropriated aspirin and clopidogrel reaction units after dual antiplatelet preparation (100 mg of aspirin and 75 mg of clopidogrel) for at least 5 days before procedure \[measured using VerifyNow\] 1. aspirin reaction unit (ARU) \< 550 2. P2Y12 reaction unit (PRU): 85\~219 * subjects who agreed to this study (with informed consent) Exclusion Criteria: * subjects with neurological deficits (mRS ≥ 3) * subjects with an allergic reaction to antiplatelets (aspirin and clopidogrel) or contrast * subjects with a high risk of hemorrhage such ICH or severe gastric ulceration * subjects with coagulopathy * subjects with thrombocytopenia (\<100,000/mm3) * subjects with liver diseases (\> 100IU/L of aspartate aminotransferase or alanine aminotransferase) * subjects with renal diseases (\> 2mg/dL of serum creatinine) * subjects with underlying diseases that need to maintain dual antiplatelet drugs or anticoagulants. * subjects with a high risk of strokes (atrial fibrillation, over 70% cerebral artery stenosis or cerebral artery occlusion, moyamoya disease, vascular malformations, etc) * subjects with uncontrolled congestive heart failure or angina * subjects with malignant tumors * subjects with a positive pregnancy test (serum or urine) * subjects who are unconscious at the time of diagnosis. * subjects who are unable to complete the required follow-ups * subjects with life-threatening diseases * subjects with medical conditions with a life expectancy of less than two years * subjects who are determined to be disqualified by researchers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aneurysm cerebral are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain aneurysm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aneurysm cerebral Endovascular procedures

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Chungnam National University Sejong Hospital

    Sejong, Chungcheongnam-do, 30099, South Korea

  • Keimyung University Dongsan Medical Center

    Daegu, 42601, South Korea

  • Pusan National University Yangsan Hospital

    Yangsan, Gyeongsangnam-do, 50612, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, 13620, South Korea

  • Soonchunhyang University Seoul Hospital

    Seoul, 04401, South Korea

  • Uijeongbu St. Mary's Hospital

    Uijeongbu-si, 11765, South Korea

  • Yonsei University Gangnam Severance Hospital

    Seoul, 06273, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.